Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness-Reference-Cited by-同舟云学术

Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness

Published:2008-01 Issue:1 Volume:7 Page:55-59
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Politano Seth,Overman Michael,Pathak Priyanka,Chadha Romil,Glover Katrina,Chang David Z.,Wolff Robert A.,Hoff Paulo M.,Abbruzzese James,Eng Cathy,Kopetz Scott

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference18 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

3. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line;Grothey;J Clin Oncol,2005

4. A phase II study of highdose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200;Giantonio;Ann Oncol,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors;Cancer Immunology, Immunotherapy;2018-08-20

2. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival;BMC Cancer;2015-09-22

3. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients;Cancer Medicine;2014-01-07

4. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells;Journal of Pharmacy and Pharmacology;2012-02-21

5. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance;Journal of Clinical Oncology;2010-01-20